Patents by Inventor Karen Cromie

Karen Cromie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 11952418
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: April 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20220362393
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 17, 2022
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Chemokine receptor binding polypeptides
    Patent number: 11466089
    Abstract: The present invention relates to polypeptides directed against or specifically binding to C—X—C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: October 11, 2022
    Assignee: Ablynx N.V.
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 11033636
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 15, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • BIPARATOPIC POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20200199222
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 25, 2020
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 10597449
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 24, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • Nucleic acids encoding chemokine receptor binding polypeptides
    Patent number: 10174118
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 8, 2019
    Assignee: Novartis AG
    Inventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
  • POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20180344868
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Chemokine receptor binding polypeptides
    Publication number: 20180022811
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: June 26, 2017
    Publication date: January 25, 2018
    Applicant: Novartis AG
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Chemokine receptor binding polypeptides
    Patent number: 9688763
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: June 27, 2017
    Assignee: Novartis AG
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • BIPARATOPIC POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20170174762
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 22, 2017
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • CHEMOKINE RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20170101476
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: June 26, 2015
    Publication date: April 13, 2017
    Applicant: Novartis AG
    Inventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE
  • Chemokine receptor binding polypeptides
    Publication number: 20160272714
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: June 26, 2015
    Publication date: September 22, 2016
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Chemokine receptor binding polypeptides
    Patent number: 9328174
    Abstract: The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 3, 2016
    Assignee: Novartis AG
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • BIOLOGIC COMPOUNDS
    Publication number: 20150259426
    Abstract: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.
    Type: Application
    Filed: November 3, 2014
    Publication date: September 17, 2015
    Inventors: Karen CROMIE, Bruno DOMBRECHT, Seth ETTENBERG, Joost Alexander KOLKMAN, Jing LI, Kris MEERSCHAERT, Jingxin ZHANG
  • Methods of treatment using chemokine receptor binding polypeptides
    Patent number: 9127067
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: September 8, 2015
    Assignee: Novartis AG
    Inventors: Michelle Bradley, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
  • Biologic compounds directed against death receptor 5
    Patent number: 9120855
    Abstract: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: September 1, 2015
    Assignee: NOVARTIS AG
    Inventors: Karen Cromie, Bruno Dombrecht, Seth Ettenberg, Joost Kolkman, Jing Li, Kris Meerschaert, David Raymond Stover, Jingxin Zhang
  • CHEMOKINE RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20140050736
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino Anselmus VAN HEEKE
  • Chemokine receptor binding polypeptides
    Publication number: 20130330346
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: May 3, 2013
    Publication date: December 12, 2013
    Inventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Chemokine receptor binding polypeptides
    Patent number: 8591896
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Van Heeke